Freenome Inc. (FRNM)
Freenome Inc. (FRNM) Stock Price, Analysis & Data
No data available
| Bid | 13.02 |
| Market Cap | 1.38B |
| Revenue (ttm) | 34.24M |
| Net Income (ttm) | -225.03M |
| Beta | 0.35 |
| EPS (ttm) | -2.07 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.02 |
| P/B (ttm) | -0.26 |
| P/S (ttm) | 40.29 |
| Earnings Date | n/a |
| Ask | 11.17 |
| Volume | 1,893,156 |
| Avg. Volume (20D) | 372,298 |
| Open | 11.50 |
| Previous Close | 11.56 |
| Day's Range | 11.49 - 13.16 |
| 52-Week Range | 9.95 - 14.47 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FRNM
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect ...
Financial Performance
In 2025, Freenome's revenue was 30.41M, an increase of 955.14% compared to the previous year's 2.88M. Earnings were -219.34M, a decrease of -20.07%.
Financial Statements
2 weeks ago · Investor's Business Daily
Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 OutlookGuardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2...